High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer

Inclusion Criteria: * Patients should have untreated metastatic colorectal cancer; prior adjuvant chemotherapy is allowed as long as the development of metastatic disease occurred more than 6 months from completion of adjuvant treatment * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 * Platelets \>= 100,000/mm\^3 * Absolute neutrophil count (ANC) \>= 1,500/mm\^3 * Hemoglobin \> 9 gm/dl * Calculated creatinine clearance \> 40 ml/min according to the Cockcroft-Gault formula OR per 24 hour urine collection * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \< 2.5 x institutional upper normal level if no liver metastases and \< 5 x upper limit of normal (ULN) in the setting of liver metastases * Total bilirubin =\< 1.5 x institutional upper normal level * Albumin \>= 2.5 g/dl * Urine protein:creatinine (UPC) ratio \< 1; in the event UPC is \> 1, the patient will require a 24-hr urine protein and will be eligible if 24-hr urine collection has \< 1,000 mg protein * Patients of child-hearing potential must agree to use acceptable contraceptive methods (e.g., double harrier) during treatment * Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board-approved written informed consent form prior to receiving any study-related procedure * Presence of measurable disease defined as a lesion \>= 1 cm by computed tomography (CT); all sites of disease should be evaluated =\< 3 weeks before treatment initiation * Baseline 25-D3 level of \< 40 ng/ml Exclusion Criteria: * Patients may not be receiving any other investigational agents that are not included in this study * Patients with known brain metastases * History of other invasive cancers with the exception of the following: a. Curatively resected or treated non-melanoma skin cancer; b. Curatively treated cervical carcinoma in situ; c. Other primary solid tumors treated curatively and no treatment administered \>= 2 years before enrollment, and in the investigator opinion, it is unlikely that there will be a recurrence =\< 1 year post enrollment * History of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaliplatin, 5-FU, leucovorin, bevacizumab, and vitamin D3 and other agents used in study * History of clinically significant bleeding within 6 months of enrollment * Clinically significant cardiovascular disease within 12 months prior to enrollment, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure or arrhythmias not controlled by outpatient medication, percutaneous transluminal coronary angioplasty/stent * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this study * Major surgery within 28 days prior to enrollment or still recovering from prior surgery * Known dihydropyrimidine dehydrogenase (DpD) deficiency * History or evidence upon physical examination of central nervous system (CNS) disease (e.g., primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of stroke) * Serious, nonhealing wound, ulcer, or bone fracture * Uncontrolled hypertension (systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 95 mmHg despite medications) * History of arterial thrombosis within the last 12 months * History of visceral arterial ischemia * Subjects unwilling or unable to comply with study requirements * Any condition that in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug * Received an investigational agent within 30 clays prior to enrollment * Treatment with vitamin D replacement with doses exceeding an average of 1000 IU/day (vitamin D3) within 60 days prior to enrollment